Neddylation tunes peripheral blood mononuclear cells immune response in COVID-19 patients.
Journal
Cell death discovery
ISSN: 2058-7716
Titre abrégé: Cell Death Discov
Pays: United States
ID NLM: 101665035
Informations de publication
Date de publication:
12 Jul 2022
12 Jul 2022
Historique:
received:
05
04
2022
accepted:
01
07
2022
revised:
29
06
2022
entrez:
13
7
2022
pubmed:
14
7
2022
medline:
14
7
2022
Statut:
epublish
Résumé
The COVID-19 pandemic caused by SARS-CoV-2 has reached 5.5 million deaths worldwide, generating a huge impact globally. This highly contagious viral infection produces a severe acute respiratory syndrome that includes cough, mucus, fever and pneumonia. Likewise, many hospitalized patients develop severe pneumonia associated with acute respiratory distress syndrome (ARDS), along an exacerbated and uncontrolled systemic inflammation that in some cases induces a fatal cytokine storm. Although vaccines clearly have had a beneficial effect, there is still a high percentage of unprotected patients that develop the pathology, due to an ineffective immune response. Therefore, a thorough understanding of the modulatory mechanisms that regulate the response to SARS-CoV-2 is crucial to find effective therapeutic alternatives. Previous studies describe the relevance of Neddylation in the activation of the immune system and its implications in viral infection. In this context, the present study postulates Neddylation, a reversible ubiquitin-like post-translational modification of proteins that control their stability, localization and activity, as a key regulator in the immune response against SARS-CoV-2. For the first time, we describe an increase in global neddylation levels in COVID-19 in the serum of patients, which is particularly associated with the early response to infection. In addition, the results showed that overactivation of neddylation controls activation, proliferation, and response of peripheral blood mononuclear cells (PBMCs) isolated from COVID-19 patients. Inhibition of neddylation, and the subsequent avoidance of activated PBMCs, reduces cytokine production, mainly IL-6 and MCP-1 and induce proteome modulation, being a critical mechanism and a potential approach to immunomodulate COVID-19 patients.
Identifiants
pubmed: 35831294
doi: 10.1038/s41420-022-01115-0
pii: 10.1038/s41420-022-01115-0
pmc: PMC9277603
doi:
Types de publication
Journal Article
Langues
eng
Pagination
316Subventions
Organisme : Ministerio de Economía, Industria y Competitividad, Gobierno de España (Ministerio de Economía, Industria y Competitividad)
ID : PID2020-117116RB-I0
Organisme : Ministerio de Economía, Industria y Competitividad, Gobierno de España (Ministerio de Economía, Industria y Competitividad)
ID : PID2019-107956RA-I00
Organisme : Fundación Científica Asociación Española Contra el Cáncer (Scientific Foundation, Spanish Association Against Cancer)
ID : PRDVZ172010SERR
Organisme : EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council)
ID : 804236 NEXTGEN-IO
Organisme : Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III)
ID : COV20/00170
Informations de copyright
© 2022. The Author(s).
Références
Commun Biol. 2021 Apr 20;4(1):486
pubmed: 33879833
Nat Rev Mol Cell Biol. 2015 Jan;16(1):30-44
pubmed: 25531226
Circ Res. 2020 Sep 17;:
pubmed: 32938299
Front Pharmacol. 2020 Jul 10;11:1095
pubmed: 32754041
J Am Coll Surg. 2021 Jun;232(6):995-1003
pubmed: 33766727
J Immunol. 2016 Apr 1;196(7):3117-23
pubmed: 26895833
Int J Cancer. 2019 Aug 1;145(3):763-774
pubmed: 31044422
Sci Rep. 2021 Nov 2;11(1):21522
pubmed: 34728658
Front Public Health. 2021 Sep 28;9:711616
pubmed: 34650947
FEBS J. 2021 Jul;288(13):3884-3912
pubmed: 33025631
Cell. 2008 Sep 19;134(6):995-1006
pubmed: 18805092
EMBO Rep. 2008 Mar;9(3):280-6
pubmed: 18274552
Mol Biol Rep. 2022 Jan;49(1):567-576
pubmed: 34643927
Antiviral Res. 2022 Jan;197:105227
pubmed: 34933044
Eur Rev Med Pharmacol Sci. 2020 Jul;24(13):7475-7484
pubmed: 32706087
Cell Mol Immunol. 2018 Mar;15(3):292-294
pubmed: 29176748
Mol Cells. 2018 Aug 31;41(8):705-716
pubmed: 30078231
Front Immunol. 2020 Feb 11;10:3154
pubmed: 32117210
Mol Cell Biol. 2015 Feb;35(3):582-97
pubmed: 25452302
Methods Enzymol. 2020;631:239-255
pubmed: 31948550
N Engl J Med. 2021 Jun 10;384(23):2212-2218
pubmed: 33882219
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Int J Mol Sci. 2021 Mar 30;22(7):
pubmed: 33808471
J Immunol. 2021 Jun 15;206(12):2900-2908
pubmed: 34049969
Leukemia. 2021 Jan;35(1):156-168
pubmed: 32203139
Front Immunol. 2020 Oct 14;11:585354
pubmed: 33163000
Cell Rep. 2019 Oct 1;29(1):212-224.e8
pubmed: 31577950
Nat Biotechnol. 2008 Dec;26(12):1367-72
pubmed: 19029910
JAMA. 2021 Feb 16;325(7):632-644
pubmed: 33475701
Nature. 2009 Apr 9;458(7239):732-6
pubmed: 19360080
Nat Commun. 2018 Oct 22;9(1):4376
pubmed: 30349034
Endocr Relat Cancer. 2015 Feb;22(1):T55-70
pubmed: 25504797
Front Pharmacol. 2020 Aug 28;11:1333
pubmed: 32982743
Immun Inflamm Dis. 2020 Dec;8(4):782-792
pubmed: 32749072
Mol Med. 2020 Oct 29;26(1):97
pubmed: 33121429
Nat Rev Immunol. 2020 Jun;20(6):355-362
pubmed: 32376901
Proc Natl Acad Sci U S A. 2013 Jan 8;110(2):624-9
pubmed: 23267066
Antioxid Redox Signal. 2009 Sep;11(9):2307-16
pubmed: 19309259
Biochem Biophys Res Commun. 2021 Jul 23;563:8-14
pubmed: 34058476
PLoS One. 2017 Feb 24;12(2):e0172987
pubmed: 28235076
Mol Syst Biol. 2014 Oct 30;10:757
pubmed: 25358341
Genome Med. 2013 Feb 28;5(2):20
pubmed: 23445784
Rev Med Virol. 2020 Nov;30(6):1-9
pubmed: 32845568
PLoS Pathog. 2021 Mar 15;17(3):e1009401
pubmed: 33720974
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
Mol Metab. 2021 Nov;53:101275
pubmed: 34153521
Nat Methods. 2016 Sep;13(9):731-40
pubmed: 27348712
Biomedicines. 2021 Jul 29;9(8):
pubmed: 34440121
PLoS Pathog. 2012;8(5):e1002717
pubmed: 22654663
Transl Gastroenterol Hepatol. 2018 Jun 30;3:37
pubmed: 30050997